For the quarter ending 2026-03-31, NKTR had $134,462K increase in cash & cash equivalents over the period. -$44,316K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 10,861 | 21,807 | 33,425 | - |
| Cost of goods sold | - | 0 | - | - |
| Rezpegaldesleukin | 20,736 | 13,643 | 37,888 | - |
| NKTRTwo Five Five | - | 1,452 | 5,034 | - |
| NKTRZero One Six Five | - | 638 | 8,931 | - |
| TNFR2Program | 798 | - | - | - |
| Discovery Research And Other Programs | -104 | 815 | 1,018 | - |
| Clinical development, contract manufacturing and other third party costs | 21,430 | 16,548 | 52,871 | - |
| Employee costs | 13,678 | 12,221 | 33,782 | - |
| Facilities costs | 2,833 | 2,928 | 9,378 | - |
| Other operating costs | 7,702 | 6,846 | 37,881 | - |
| Other segment expenses | 4,272 | 10,929 | 11,950 | - |
| Gain on sale of the huntsville manufacturing facility | - | 0 | - | - |
| Total operating costs and expenses | 49,915 | 49,472 | 145,862 | - |
| Loss from operations | -39,054 | -27,665 | -112,437 | - |
| Non-cash interest expense on liabilities related to the sales of future royalties | 7,942 | 9,769 | 6,047 | - |
| Interest income | 4,242 | 2,776 | 7,662 | - |
| Other income (expense), net | -336 | -44 | 405 | - |
| Total non-operating income (expense), net | -4,036 | -7,037 | -8,348 | - |
| Loss before provision for income taxes and equity method investment | -43,090 | -34,702 | -120,785 | - |
| Provision for income taxes | 64 | 31 | -169 | - |
| Impairment of right-of-use assets and property, plant and equipment | - | 4,441 | 0 | 0 |
| Loss before equity method investment | -43,154 | -34,733 | -120,616 | - |
| Gain on sale of the huntsville manufacturing facility | - | 0 | - | - |
| Loss from equity method investment | -1,750 | -1,346 | -534 | - |
| Provision for net realizable value of inventory | - | 0 | 0 | 0 |
| Net loss | -44,904 | -36,079 | -35,522 | -92,475 |
| Non-cash royalty revenue related to the sales of future royalties | 10,861 | 21,807 | 11,490 | 21,635 |
| Non-cash interest expense on liabilities related to the sales of future royalties | 7,942 | 9,769 | 6,047 | 10,368 |
| Loss from equity method investment | -1,750 | -1,346 | -534 | -6,847 |
| Stock-based compensation | 3,355 | 2,193 | 3,072 | 7,384 |
| Depreciation and amortization expense | 151 | 190 | 196 | 640 |
| Amortization of premiums (discounts), net | -1,663 | -1,888 | -1,433 | -2,193 |
| Accounts receivable | - | 0 | 0 | 0 |
| Inventory | - | 0 | 0 | 0 |
| Operating leases, net | 2,409 | 5,750 | 3,827 | 5,580 |
| Other assets | -949 | 9,858 | 618 | 4,973 |
| Accounts payable | -934 | -4,793 | 1,282 | 2,886 |
| Accrued expenses | 2,326 | -2,723 | -7,002 | 3,940 |
| Net cash used in operating activities | -44,298 | -64,959 | -48,761 | -94,791 |
| Purchases of investments | 452,253 | 91,602 | 149,558 | 43,852 |
| Maturities of investments | 101,482 | 91,992 | 54,799 | 137,892 |
| Proceeds (payments) relating to the sale of the huntsville manufacturing facility, net | - | -697 | - | - |
| Purchases of property and equipment | 18 | 18 | 114 | 39 |
| Payment of transaction costs and working capital adjustment from the sale of the huntsville manufacturing facility | -697 | - | 0 | 697 |
| Net cash provided by (used in) investing activities | -350,789 | 372 | -94,873 | 93,304 |
| Proceeds from issuance of tcg pre-funded warrant | - | 0 | 0 | 0 |
| Proceeds from sale of future royalties | - | 0 | 0 | 0 |
| Repurchase of common stock from bristol-myers squibb | - | 0 | 0 | 0 |
| Proceeds from shares issued under equity compensation plans | 4,055 | 410 | 238 | 218 |
| Proceeds from offering, net-Two Thousand Twenty Five Secondary Public Offering | - | 0 | 108,100 | - |
| Proceeds from offering, net-Underwritten Offering | 432,400 | - | - | - |
| Proceeds from offering, net-At The Market Offerings | - | 72,750 | - | - |
| Proceeds from offering, net-At The Market Offering | 58,630 | - | 34,489 | - |
| Payments of offering costs associated with issuance of common stock and pre-funded warrants | 25 | 0 | 1,150 | - |
| Net cash provided by financing activities | 529,549 | 38,671 | 141,677 | 218 |
| Effect of foreign exchange rates on cash and cash equivalents | 0 | 0 | 1 | 5 |
| Net increase (decrease) in cash and cash equivalents | 134,462 | -25,916 | -1,956 | -1,264 |
| Cash and cash equivalents at beginning of period | 15,116 | 41,032 | 44,252 | - |
| Cash and cash equivalents at end of period | 149,578 | 15,116 | 41,032 | - |
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)